Compositions and methods for treatment of chronic lung diseases

A vector comprising a nucleic acid molecule comprising one or more polynucleotides encoding:

• a) MEGF9 or a biologically active fragment thereof;
• b) UNC5A or a biologically active fragment thereof;
• c) ALG5 or a biologically active fragment thereof;
• d) a combination two or three of any of a-c;
• e) an antibody specifically binding to a);
• f) an antibody specifically binding to b);
• g) an antibody specifically binding to c);
• h) a combination of two or three of e)-g);
• or
• a combination of at least one of a)-c) and at least one of e)-g),
• wherein the MEGF9 comprises the sequence of SEQ ID NO:
• 1, or a sequence with at least 80%, at least 85%, at least 90%, or at least 95% sequence identity to SEQ ID NO:
• 1,
• wherein the UNC5A comprises the sequence of SEQ ID NO:
• 5, or a sequence with at least 80% sequence identity to SEQ ID NO:
• 5,
• wherein the ALG5 comprises the sequence of SEQ ID NO:
• 9, or a sequence with at least 80% sequence identity to SEQ ID NO:
• 9,
• wherein the biologically active fragment of the MEGF9 comprises the sequence of SEQ ID NO:
• 3, or a sequence with at least 80% sequence identity to SEQ ID NO:
• 3,
• wherein the biologically active fragment of the MEGF9 comprises the sequence of SEQ ID NO:
• 4, or a one-amino acid or two-amino acid modification thereof,
• wherein the biologically active fragment of the MEGF9 comprises the sequence of SEQ ID NO:
• 102, or a sequence with at least 80% sequence identity to SEQ ID NO:
• 102,
• wherein the biologically active fragment of the UNC5A comprises the sequence of SEQ ID NO:
• 7, or a sequence with at least 80% sequence identity to SEQ ID NO:
• 7,
• wherein the biologically active fragment of the UNC5A comprises the sequence of SEQ ID NO:
• 8, or a sequence with at least 80% sequence identity to SEQ ID NO:
• 8,
• wherein the biologically active fragment of the UNC5A comprises the sequence of SEQ ID NO:
• 103, or a sequence with at least 80% sequence identity to SEQ ID NO:
• 103,
• i) wherein the biologically active fragment of the ALG5 comprises the sequence of SEQ ID NO:
• 104, or a sequence with at least 80% sequence identity to SEQ ID NO:
• 104.

A pharmaceutical composition comprising a pharmaceutically acceptable carrier and

• a) MEGF9 or a biologically active fragment thereof;
• b) UNC5A or a biologically active fragment thereof;
• c) ALG5 or a biologically active fragment thereof;
• d) a combination of two or three of a)-c);
• e) an antibody specific for a);
• f) an antibody specific for b);
• g) an antibody specific for c);
• h) a combination of two or three of e)-g);
• or
• i) a combination of at least one of a)-c) and at least one of e)-g),
• wherein the MEGF9 comprises the sequence of SEQ ID NO:
• 1, or a sequence with at least 80%, at least 85%, at least 90%, or at least 95% sequence identity to SEQ ID NO:
• 1,
• wherein the UNC5A comprises the sequence of SEQ ID NO:
• 5, or a sequence with at least 80% sequence identity to SEQ ID NO:
• 5,
• wherein the ALG5 comprises the sequence of SEQ ID NO:
• 9, or a sequence with at least 80% sequence identity to SEQ ID NO:
• 9,
• wherein the biologically active fragment of the MEGF9 comprises the sequence of SEQ ID NO:
• 3, or a sequence with at least 80% sequence identity to SEQ ID NO:
• 3,
• wherein the biologically active fragment of the MEGF9 comprises the sequence of SEQ ID NO:
• 4, or a one-amino acid or two-amino acid modification thereof,
• wherein the biologically active fragment of the MEGF9 comprises the sequence of SEQ ID NO:
• 102, or a sequence with at least 80% sequence identity to SEQ ID NO:
• 102,
• wherein the biologically active fragment of the UNC5A comprises the sequence of SEQ ID NO:
• 7, or a sequence with at least 80% sequence identity to SEQ ID NO:
• 7,
• wherein the biologically active fragment of the UNC5A comprises the sequence of SEQ ID NO:
• 8, or a sequence with at least 80% sequence identity to SEQ ID NO:
• 8,
• wherein the biologically active fragment of the UNC5A comprises the sequence of SEQ ID NO:
• 103, or a sequence with at least 80% sequence identity to SEQ ID NO:
• 103,
• wherein the biologically active fragment of the ALG5 comprises the sequence of SEQ ID NO:
• 104, or a sequence with at least 80% sequence identity to SEQ ID NO:
• 104.